"On a proforma basis for the full-year 2012, we launched more than 1,000 generic products globally, and filed more than 1,500 applications globally. Our Actavis Pharma pipeline is among the strongest in the industry with over 185 ANDAs on file with the U.S. FDA, including 49 first-to-file opportunities, of which, 33 represent potential exclusive first-to-files."
"In our Actavis Specialty Brands business, we experienced growth from U.S. sales of our key promoted products including Rapaflo®, Crinone®, and Generess® Fe.
We expanded our brand portfolio globally as we launched Rapaflo®, Gelnique®, Androderm® and Oxytrol® in Canada and prepared for launches of key branded products in Latin America. We continued to record progress in our biosimilar initiatives as we acquired a biosimilar to Herceptin® from Synthon and contributed the product to the Amgen collaboration which includes Herceptin®, Avastin®, Rituxan/MabThera® and Erbitux®. Additionally, rFSH entered into the Phase I clinical program."
In January 2013, we acquired Uteron Pharma SA which adds three near term and three longer term projects to our Women's Health development portfolio," Bisaro continued.
"In 2012, we continued to utilize our strong balance sheet as we issued $3.9 billion in senior unsecured notes and completed a new $1.8 billion term loan facility at favorable rates. We are focused on repaying our debt and maintaining a strong financial foundation to support strategic growth initiatives within our global businesses," concluded Bisaro.
Fourth Quarter and Full Year 2012 Business Segment ResultsActavis Pharma Segment InformationThree Months EndedTwelve Months Ende
|SOURCE Actavis, Inc.|
Copyright©2012 PR Newswire.
All rights reserved